首页 | 本学科首页   官方微博 | 高级检索  
     

草乌甲素片治疗轻中度癌痛多中心、随机对照、非劣效性研究
引用本文:王薇,李杰,刘航,孙红,李宝兰,吴晓明,李萍萍. 草乌甲素片治疗轻中度癌痛多中心、随机对照、非劣效性研究[J]. 中国疼痛医学杂志, 2021, 0(3): 188-195
作者姓名:王薇  李杰  刘航  孙红  李宝兰  吴晓明  李萍萍
作者单位:北京大学肿瘤医院暨北京市肿瘤防治研究所中西医结合科;首都医科大学附属医院胸科医院综合科;北京市朝阳区桓兴肿瘤医院麻醉科;中国医学科学院肿瘤医院综合科
基金项目:CSCO-丽珠中医药肿瘤研究基金(Y-L2012-002);北京市属医院科研培育计划(PZ2016024)。
摘    要:目的:通过多中心、随机、对照、非劣效性临床研究,证实草乌甲素的疗效.方法:随机数字表法区组随机筛选病例.病人1:1分入对照组和试验组.三家研究中心共筛选入组轻度癌痛32例(对照组16例,试验组16例),中度癌痛63例(对照组29例,试验组34例).对照组口服布洛芬缓释胶囊或曲马多缓释片、试验组口服草乌甲素片.观察时间7...

关 键 词:癌性疼痛  草乌甲素  镇痛  中医药  RCT研究

A multi-center,randomized,controlled,non-inferiority clinical study of bulleyaconitine A in the treatment of mild and moderate cancer pain
WANG Wei,LI Jie,LIU Hang,SUN Hong,LI Bao-Lan,WU Xiao-Ming,LI Ping-Ping. A multi-center,randomized,controlled,non-inferiority clinical study of bulleyaconitine A in the treatment of mild and moderate cancer pain[J]. Chinese Journal of Pain Medicine, 2021, 0(3): 188-195
Authors:WANG Wei  LI Jie  LIU Hang  SUN Hong  LI Bao-Lan  WU Xiao-Ming  LI Ping-Ping
Affiliation:(Key laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Integrated Chinese and Western Medicine,Peking University Cancer Hospital&Institute,Beijing 100142,China;General Department,Beijing Chest Hospital,Capital Medical University,Beijing 101149,China;Department of Anesthesiology,Beijing Chaoyang Huanxing Cancer Hospital,Beijing 100005,China;General Department,Cancer Hospital Chinese Academy of Medical Sciences,Beijing 100021,China)
Abstract:Objective:The efficacy of bulleyaconitine A in the treatment of mild and moderate cancer pain was confirmed by multicenter,randomized,controlled and non-inferior clinical research.Methods:The cases were randomly screened with random-number table,and all patients registrated at the general centre.Patients were divided into the control group and the experimental group(1:1).A total of 32 cases of mild cancer pain(16 cases in the control group and 16 cases in the experimental group)and 63 cases of moderate cancer pain(29 cases in the control group and 34 cases in the experimental group)were screened in the three centers.The age,sex,body mass index(BMI),nature of pain,and ID-pain scale were not statistically different between the control group and the experimental group.The control group took Ibuprofen sustained-release capsules(mild)or tramadol sustained-release tablets(moderate),and the experimental group took Bulleyaconitine A tablets.They were observed for 7 days.Results:Mean daily pain numerical rating scale(NRS)score showed no difference between the control group and the experimental group in the patients with mild cancer pain.The control group of patients with moderate cancer pain was lower than the experimental group on the 4th day,and there was no difference between the two groups in the rest time points.There were 14 cases with adverse reactions in the control group and 2 cases in the experimental group,with significant difference.The assessment of life quality of patients with moderate cancer pain showed better emotional function and lower pain and diarrhea symptom scores.Conclusion:Patients with mild to moderate cancer pain can be considered to choose Bulleyaconitine A if the drugs in the first step and the second step are ineffective or intolerant。
Keywords:Cancer pain  Bulleyaconitine A  Analgesia  TCM  RCT research
本文献已被 维普 等数据库收录!
点击此处可从《中国疼痛医学杂志》浏览原始摘要信息
点击此处可从《中国疼痛医学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号